Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials

202133 citationsJournal Articlegold Open Access

Authors

Rebecca F. Grais

Stephen B. Kennedy · Planned Parenthood Association of Liberia

Barbara E. Mahon · Centers for Disease Control and Prevention

Sheri Dubey · Merck & Co., Inc., Rahway, NJ, USA (United States)

Rebecca J. Grant-Klein · Merck & Co., Inc., Rahway, NJ, USA (United States)

Ken Liu · Merck & Co., Inc., Rahway, NJ, USA (United States)

Jonathan Hartzel ·

Abstract

Merck Sharp & Dohme, Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services.

Topics & Keywords

Viral Infections and Outbreaks Research Viral Infections and Vectors Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Lancet Microbe

Volume 2, Issue 2, pp. e70-e78

DOI: 10.1016/s2666-5247(20)30198-1

Field-Weighted Citation Impact: 1.56